IDEXX Expands Diagnostic Capabilities to Enhance Veterinary Care

IDEXX Laboratories (NASDAQ:IDXX) has expanded its Fecal Dx antigen testing platform to include detection of taeniid tapeworm species, enhancing early identification of intestinal parasites. Additionally, the company integrated SDMA renal biomarker into Catalyst CLIPs for improved kidney function evaluation in pets.

By Sajjl Nooranne Mon, June 22, 2026 at 4:31 PM GMT+3 2 min read · Yahoo Finance · June 22, 2026, 13:31 UTC

IDEXX Expands Diagnostic Capabilities to Enhance Veterinary Care

Tickers: $IDXX

Topics: Healthcare Innovation Veterinary Diagnostics

Read the full article at Yahoo Finance

More World news

Oman Investment Authority Signs Multi-Billion Dollar Investment Package with Chinese Partners PR Newswire · November 12, 2026, 15:52 UTC
Nvidia Shares Drop 35% Following Resignation of CEO Jensen Huang Motley Fool · November 12, 2026, 15:49 UTC
Pomerantz Law Firm Investigates Potential Securities Fraud at ClearPoint Neuro (CLPT) PR Newswire · November 12, 2026, 15:50 UTC
Nvidia CEO Jensen Huang Resigns Amid Board Investigation The Verge · November 12, 2026, 15:48 UTC
GFL Environmental Shares Decline Following Preferred Share Conversion and Block Trade Seeking Alpha · November 12, 2026, 15:48 UTC
Medical Facilities Corp. Announces CAD 0.09 Per Share Quarterly Dividend Seeking Alpha · November 12, 2026, 15:45 UTC
Micron Shares Decline Following Resignation of Nvidia CEO Jensen Huang Motley Fool · November 12, 2026, 15:44 UTC
Wirex Launches Navoka AI Agent with Dedicated Bank Account and Card PR Newswire · November 12, 2026, 15:44 UTC
Mobility Global Shares Rise 12% Following Q3 Earnings Beat and Improved EBITDA Outlook Seeking Alpha · November 12, 2026, 15:44 UTC
Lucid Diagnostics Reports Q3 2026 Results Amid Transition to Medicare Reimbursement Motley Fool · November 12, 2026, 15:39 UTC